Adaptimmune designs, develops, and delivers T-cell therapies for solid tumors. By engineering T-cell receptors (TCRs) to a high affinity against cancer antigens, the Company has built a broad pipeline to target solid tumors. As an integrated cell therapy company, Adaptimmune uses in-house manufacturing capabilities to introduce its proprietary engineered TCRs into patient’s own T-cells, thus empowering a person’s own immune system to fight their disease. With added next-generation enhancements to improve efficacy, and a rapidly developing allogeneic program to provide off-the-shelf T-cell therapies to any eligible patient, Adaptimmune is at the forefront of immuno-oncology.
The European Laboratory Research & Innovation Group
Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Get the App
Get this event information on your mobile by going to the Apple or Google Store and search for 'myEventflo'